Head-To-Head Survey: Nuwellis (NASDAQ:NUWE) vs. Alpha Tau Medical (NASDAQ:DRTS)

Alpha Tau Medical (NASDAQ:DRTS) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Valuation & Earnings

This table compares Alpha Tau Medical and Nuwellis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$31.75 million	($0.52)	-13.44
Nuwellis	$8.74 million	0.42	-$11.16 million	($107.91)	-0.02

Nuwellis has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alpha Tau Medical and Nuwellis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-56.45%	-41.76%
Nuwellis	-202.83%	-1,367.63%	-202.97%

Analyst Ratings

This is a summary of recent ratings and target prices for Alpha Tau Medical and Nuwellis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	2	0	2	0	2.00
Nuwellis	1	0	1	0	2.00

Alpha Tau Medical presently has a consensus target price of $8.00, indicating a potential upside of 14.45%. Given Alpha Tau Medical’s higher possible upside, equities analysts plainly believe Alpha Tau Medical is more favorable than Nuwellis.

Institutional & Insider Ownership

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 20.1% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Alpha Tau Medical has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.

Summary

Alpha Tau Medical beats Nuwellis on 8 of the 12 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.